Osanni Bio, a biotech firm dedicated to reversing and preventing blindness, has secured $50.0M in funding from Merck KGaA. The investment will fuel the company's distinctive approach to tackling retinal diseases, which are often multi-factorial and complex.
Describing itself as "Designed for Sight," Osanni Bio aims to bring creativity to science through design thinking, developing therapies in areas where others aren't. Its mission is to create fundamentally different solutions for sight-threatening conditions, ultimately changing the future of vision.















